# Emergent BioSolutions Inc.: Form 10-K/A for the period ended Dec 31, 2014

- Company: [Emergent BioSolutions Inc.](/companies/ebs.md) (CIK 1367644)
- Form: 10-K/A
- Filed: 2015-03-09
- Accepted by EDGAR: Mar 9, 2015, 09:42 ET
- Period: 2014-12-31
- Accession: 0001367644-15-000019
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1367644/000136764415000019/form10k_a.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1367644/000136764415000019/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-10-01 to 2014-12-31 | $148.0m | us-gaap:SalesRevenueNet |
| Revenue | 12 months, 2014-01-01 to 2014-12-31 | $450.1m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2014-01-01 to 2014-12-31 | $118.4m | us-gaap:CostOfGoodsSold |
| Research and development | 12 months, 2014-01-01 to 2014-12-31 | $150.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2014-01-01 to 2014-12-31 | $122.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2014-10-01 to 2014-12-31 | $44.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months, 2014-01-01 to 2014-12-31 | $58.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2014-01-01 to 2014-12-31 | $8.2m | us-gaap:InterestExpense |
| Income tax | 12 months, 2014-01-01 to 2014-12-31 | $16.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-10-01 to 2014-12-31 | $30.1m | us-gaap:NetIncomeLoss |
| Net income | 12 months, 2014-01-01 to 2014-12-31 | $36.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-10-01 to 2014-12-31 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months, 2014-01-01 to 2014-12-31 | $0.88 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-10-01 to 2014-12-31 | $0.80 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months, 2014-01-01 to 2014-12-31 | $0.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2014-01-01 to 2014-12-31 | 45,802,807 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2014-01-01 to 2014-12-31 | $112.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2014-01-01 to 2014-12-31 | $30.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months, 2014-01-01 to 2014-12-31 | $200.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2014-12-31 | $280.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-12-31 | $432.2m | us-gaap:AssetsCurrent |
| Total assets | at 2014-12-31 | $945.3m | us-gaap:Assets |
| Current liabilities | at 2014-12-31 | $92.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-12-31 | $392.1m | us-gaap:Liabilities |
| Long-term debt | at 2014-12-31 | $251.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2014-12-31 | $553.2m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1367644/000136764415000019/form10k_a.htm

Filed Mar 9, 2015.
Source: SEC EDGAR, the filing index for accession 0001367644-15-000019. Last ingested by Listed: Nov 4, 2026, 16:51 ET. No prices; not investment advice.
